Immunex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 05-01-2025
- Paid Up Capital ₹ 9.38 M
as on 05-01-2025
- Company Age 30 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -15.33%
(FY 2021)
- Profit 6156.51%
(FY 2021)
- Ebitda 34.92%
(FY 2021)
- Net Worth 0.39%
(FY 2021)
- Total Assets 0.15%
(FY 2021)
About Immunex Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.38 M, as per Ministry of Corporate Affairs (MCA) records.
Rajiv Bohra, Shivam Bohra, and Ashutosh Bohra serve as directors at the Company.
- CIN/LLPIN
U51392MH1994PTC078973
- Company No.
078973
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Immunex Pharmaceuticals Private Limited offer?
Immunex Pharmaceuticals Private Limited offers a wide range of products and services, including Warehousing Services, Goods Warehousing Service.
Who are the key members and board of directors at Immunex Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivam Bohra  | Director | 14-Feb-2020 | Current |
| Ashutosh Bohra | Director | 10-Feb-2023 | Current |
| Rajiv Bohra | Director | 02-Sep-2013 | Current |
Financial Performance of Immunex Pharmaceuticals.
Immunex Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 15.33% decrease. The company also saw a substantial improvement in profitability, with a 6156.51% increase in profit. The company's net worth moved up by a moderate rise of 0.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immunex Pharmaceuticals?
In 2018, Immunex Pharmaceuticals had a promoter holding of 0.21% and a public holding of 99.79%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Bijul Pharmachem Private LimitedActive 33 years 8 months
Rajiv Bohra, Shivam Bohra and 1 more are mutual person
- Alliance Soaps Private LimitedActive 16 years 1 month
Rajiv Bohra and Shivam Bohra are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immunex Pharmaceuticals?
Unlock and access historical data on people associated with Immunex Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immunex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
